Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Cat. No. : AD00122Z
Storage : -80℃ Shipping : Frozen on dry ice
Titer: Size:
| Cat. No. | AD00122Z |
| Product Type | Adenoviral particle |
| Gene | APOE |
| Titer | Varies lot by lot, for example, ≥1x10^10 IFU/mL, ≥1x10^11 IFU/mL, ≥1x10^11 VP/mL etc. |
| Size | Varies lot by lot, for example, 100 ul, 500 ul, 1 mL etc. |
| Storage | Store at -80℃. Avoid multiple freeze/thaw cycles. |
| Shipping | Frozen on dry ice |
| Summary | Creative Biogene ensures high-quality adenovirus particles by optimizing and standardizing production protocols and performing stringent quality control (QC). The specific QC experiments performed vary between adenovirus particle lots. |
| Endotoxin | Endotoxins, primarily derived from Gram-negative bacteria, can trigger adverse immune responses. Endotoxin contamination is a significant concern in adenovirus production, especially for applications in animal studies and gene therapy. Creative Biogene utilizes rigorous endotoxin detection methods to monitor the endotoxin level in our produced adenovirus particles to ensure regulatory compliance. |
| Sterility | Creative Biogene ensures that adenovirus products are free of any bacterial, fungal and other microbial contamination. |
| Ad5 E1 Detection | All Creative Biogene adenoviruses are PCR tested to ensure that there are no detectable E1 sequences in the particles, which could be from revertants or external E1 contamination. |
| RCA Assays | Adenovirus products originating at Creative Biogene are guaranteed to have undetectable replication-competent adenovirus (RCA). This quality control measure is important because there is always the possibility of wild-type contamination due to revertants or environmental sources. |
| PFU Titering | All purified adenovirus preparations are tested for infectious titer. Creative Biogene's PFU test takes a few days longer but counts true plaques in HEK cells rather than estimating PFU titers via IHC staining or TCI50 of infected cells. |
| Gene Name | APOE apolipoprotein E [ Homo sapiens ] |
| Gene Symbol | APOE |
| Synonyms | AD2; LPG; LDLCQ5 |
| Gene Description | apolipoprotein E |
| GeneID | 348 |
| Uni ProtID | P02649 |
| mRNA Refseq | NM_000041.2 |
| Protein Refseq | NP_000032.1 |
| Chromosome Location | 19q13.2 |
| Function | antioxidant activity; beta-amyloid binding; heparin binding; identical protein binding; lipid binding; lipid transporter activity; low-density lipoprotein particle receptor binding; low-density lipoprotein particle receptor binding; metal chelating activity; phosphatidylcholine-sterol O-acyltransferase activator activity; phospholipid binding; protein binding; protein heterodimerization activity; protein homodimerization activity; tau protein binding; very-low-density lipoprotein particle receptor binding; very-low-density lipoprotein particle receptor binding; |
| Pathway | Alzheimers disease, organism-specific biosystem; Alzheimers disease, conserved biosystem; Alzheimers Disease, organism-specific biosystem; Chylomicron-mediated lipid transport, organism-specific biosystem; HDL-mediated lipid transport, organism-specific biosystem; Lipid digestion, mobilization, and transport, organism-specific biosystem; Lipoprotein metabolism, organism-specific biosystem; |
| MIM | 107741 |
The human apolipoprotein E (APOE) gene is located on chromosome 19 and encodes a key protein that is primarily synthesized in the liver and brain and plays an important role in lipid metabolism and transport. APOE acts as a ligand for specific cell surface receptors, facilitating the uptake and clearance of cholesterol-rich lipoprotein particles such as chylomicrons and very low-density lipoprotein (VLDL) remnants from the blood. This function is essential for maintaining lipid homeostasis and preventing atherosclerosis. In addition to its systemic metabolic effects, APOE is abundantly expressed in brain tissue, composed of astrocytes and microglia, where it participates in the redistribution of cholesterol, which is essential for neuronal repair, synapse formation, and overall brain plasticity. Crucially, there are three major isoforms of the APOE gene (ε2, ε3, ε4), which are defined by single nucleotide polymorphisms. The ε3 allele is the most common, while the ε4 allele is the strongest known genetic risk factor for late-onset Alzheimer''s disease (AD), significantly increasing susceptibility and potentially reducing the age of onset. In contrast, the ε2 allele appears to have some protective effect against AD.
Human APOE adenoviral particles are complex recombinant viral vectors that have been specifically engineered to deliver and express the human APOE gene in target cells or tissues in vitro or in vivo. These particles are constructed using a modified adenoviral backbone, usually derived from human adenovirus serotype 5 (Ad5), in which the viral genes essential for replication (the E1 region and usually the E3 region) are deleted. The main advantage of adenoviral vectors is their high transduction efficiency in a wide range of dividing and non-dividing cell types, including primary neurons, hepatocytes, and macrophages, which are notoriously difficult to transfect. They provide high levels of transient transgene expression, making them ideal for acute functional studies, disease modeling (e.g., studying the effects of APOE4 on neurons or astrocytes), studying lipid metabolism pathways in hepatocytes, or exploring therapeutic strategies in relevant preclinical models. In summary, human APOE adenoviral particles are an indispensable tool for dissecting APOE isoform-specific functions, modeling related diseases such as AD and atherosclerosis, and evaluating potential gene therapies or mechanistic pathways in a controlled experimental setting.
Macrophages play an important role in the pathogenesis of atherosclerosis, but their dynamics within plaques remain unclear. In stable in vivo preparations, large asymmetric foamy macrophages in the intima of carotid plaques are stationary, but smaller round cells near the plaque edge, likely newly recruited monocytes, move laterally along the plaque edge. Here, to test the dynamics of macrophages in plaques over longer periods of time during disease progression and regression, researchers quantified the displacement of nondegradable phagocytic particles within macrophages for up to 6 weeks. By measuring the distance of the particles from the base of the plaque, researchers found that the distance of the particles from the base remained constant regardless of plaque progression or regression. The significantly deeper penetration of labeled cells in progressive disease can be attributed to monocyte recruitment, which creates a new macrophage surface layer over the labeled phagocytic cells. Although individual exceptions may exist, as a group, newly differentiated macrophages are unable to penetrate deeper than the limited depth to which they initially enter, regardless of plaque progression or regression. These limiting dynamics may prevent macrophages from escaping areas of adverse conditions (e.g., hypoxia) and pose a challenge for newly recruited macrophages to clear debris via endocytosis deep within the plaque.
Previous studies have shown that macrophage loss from plaques can be triggered by virally induced ApoE expression in plaque-bearing ApoE−/− mice. Viral transduction with adeno-associated virus 8-ApoE was effective in rapidly and stably reversing plasma cholesterol levels in male mice. In this model, macrophage-borne particles are not removed from plaques during macrophage loss. Therefore, migratory efflux of macrophages is not necessary for their removal, and such migration did not occur in this model. However, subsequent closer examination of plaque sections from these experiments revealed a striking pattern, whereby particles appeared distant from the lumen during disease progression (empty adenoviral vector; Figure 1Aa), whereas particles appeared close to the lumen in resolving treatments (ApoE-encoding adenoviral vector (ad-hApoE3); Figure 1Bb). Importantly, beads were observed to be abundantly present in the cytoplasm of macrophages within plaques in both treatment conditions (Figure 1C). Indeed, quantification of the particle-to-lumen distance confirmed a deeper localization of particles in the empty adenoviral vector group compared to the ad-hApoE3 group (Figure 1D). It was further confirmed that there was no statistical difference in total bead counts among the groups (Figure 1E).
Figure 1. Positional tracking using phagocytic cargo labeling suggests little displacement of central plaque macrophages over several weeks during plaque progression or regression. (Williams J W, et al., 2018)
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
The pre-titered viral stock saved us time, and the clear documentation made optimization seamless. Highly recommend for Alzheimer’s disease models!
Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.